The agreement with AstraZeneca grants the British multinational exclusive global rights, excluding China, to develop and manufacture TQC3721, a new PDE3/4 inhibitor designed to relax airway muscles and reduce inflammation. Sino Biopharmaceutical stands to gain an immediate $200 million payment, with additional milestone incentives potentially pushing the deal’s total value to $1.9 billion, alongside tiered double-digit royalties on future net sales.

Simultaneously, the Beijing-based firm is deepening its existing ties with GSK by taking over the distribution, hospital access, and promotion of respiratory drugs Trelegy Ellipta and Anoro Ellipta within mainland China. Markets reacted positively to the news, with Sino Biopharmaceutical’s stock climbing as much as 6.8% in Hong Kong trading. These partnerships underscore a deepening integration between multinational pharmaceutical entities and Chinese biotech, as global players look to capitalize on the country's accelerating drug-development capabilities and cost-efficient research infrastructure.